IBRUTINIB IN MONOTHERAPY AS A TREATMENT OF RELAPSED MANTLE CELL LYMPHOMA IN THE CENTRAL NERVOUS SYSTEM. CASE REPORT

被引：0
|
作者：
Morales de la Plaza, A. [1 ]
Santero Garcia, M. [1 ]
Sebrango Sadia, A. [1 ]
机构：
[1] Hosp Univ Torrejon, Madrid, Spain
来源：
HAEMATOLOGICA | 2018年 / 103卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PB-060
引用
收藏
页码：337 / 337
页数：1
相关论文
共 50 条
  • [31] IBRUTINIB MONOTHERAPY IN RELAPSED/REFRACTORY CNS LYMPHOMA: A RETROSPECTIVE CASE SERIES
    Chamoun, Kamal
    Choquet, Sylvain
    Boyle, Eileen
    Houillier, Caroline
    Larrieu-Ciron, Delphine
    Al Jijakli, Ahmad
    Delrieu, Vanessa
    Delwail, Vincent
    Morschhauser, Franck
    Hoang-Xuan, Khe
    Soussain, Carole
    NEUROLOGY, 2017, 88 (01) : 101 - 102
  • [32] A Phase II Trial of Nivolumab and Ibrutinib for Patients with Relapsed or Refractory Central Nervous System Lymphoma
    Westin, Jason R.
    Fowler, Nathan H.
    Nastoupil, Loretta J.
    Neelapu, Sattva S.
    Lee, Hun Ju
    Hagemeister, Fredrick B.
    Rodriguez, Maria Alma
    Steiner, Raphael E.
    Ahmed, Sairah
    Parmar, Simrit
    Nair, Ranjit
    Harrison, Rebecca
    Fayad, Luis
    BLOOD, 2019, 134
  • [33] Central nervous system involvement in patients with mantle cell lymphoma
    Oinonen, R
    Franssila, K
    Elonen, E
    ANNALS OF HEMATOLOGY, 1999, 78 (03) : 145 - 149
  • [34] Central nervous system involvement in patients with mantle cell lymphoma
    R. Oinonen
    K. Franssila
    E. Elonen
    Annals of Hematology, 1999, 78 : 145 - 149
  • [35] Isolated central nervous system relapse in mantle cell lymphoma
    Chiriac, Radu
    Gross, Zofia
    EJHAEM, 2025,
  • [36] Primary lymphoma of the central nervous system.
    Rana, PA
    Rana, RJ
    Salvarezza, A
    MEDICINA-BUENOS AIRES, 1997, 57 (05) : 645 - 645
  • [37] Ibrutinib monotherapy as effective treatment of central nervous system involvement by chronic lymphocytic leukaemia
    Tam, Constantine S.
    Kimber, Thomas
    Seymour, John F.
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 176 (05) : 829 - 831
  • [38] A retrospective analysis of ibrutinib outcomes in relapsed or refractory mantle cell lymphoma
    Lee, Yong-Pyo
    Jung, Ye Ji
    Cho, Junhun
    Ko, Young Hyeh
    Kim, Won Seog
    Kim, Seok Jin
    Yoon, Sang Eun
    BLOOD RESEARCH, 2023, 58 (04) : 208 - 220
  • [39] Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: Precog 0404
    Cohen, Jonathon B.
    Jegede, Opeyemi
    Portell, Craig A.
    Hamadani, Mehdi
    Diefenbach, Catherine S.
    David, Kevin A.
    Fletcher, Christopher D.
    Landsburg, Daniel J.
    Mantha, Suparna
    Kahl, Brad S.
    BLOOD, 2022, 140 : 6487 - 6488
  • [40] Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
    Wang, Michael L.
    Rule, Simon
    Martin, Peter
    Goy, Andre
    Auer, Rebecca
    Kahl, Brad S.
    Jurczak, Wojciech
    Advani, Ranjana H.
    Romaguera, Jorge E.
    Williams, Michael E.
    Barrientos, Jacqueline C.
    Chmielowska, Ewa
    Radford, John
    Stilgenbauer, Stephan
    Dreyling, Martin
    Jedrzejczak, Wieslaw Wiktor
    Johnson, Peter
    Spurgeon, Stephen E.
    Li, Lei
    Zhang, Liang
    Newberry, Kate
    Ou, Zhishuo
    Cheng, Nancy
    Fang, Bingliang
    McGreivy, Jesse
    Clow, Fong
    Buggy, Joseph J.
    Chang, Betty Y.
    Beaupre, Darrin M.
    Kunkel, Lori A.
    Blum, Kristie A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (06): : 507 - 516
12345